In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor monotherapyUtility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapyMonitoring for and managing immune-related adverse events during the COVID-19 pandemic Presenters:Petros Grivas, MD, PhDAssociate ProfessorClinical Director, Genitourinary Cancers ProgramDivision of Medical OncologyDepartment of MedicineUniversity of WashingtonSeattle Cancer Care AllianceSeattle, Washington, USAJonathan E. Rosenberg MDAttending PhysicianChief, Genitourinary Oncology ServiceDivision of Solid Tumor OncologyDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New York, USAContent based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand Webcast:http://bit.ly/3kJC5SL

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related